Universal Technical Institute - UTI Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Universal Technical Institute in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" UTI shares.
View UTI analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 1 year price objectives for Universal Technical Institute's shares. Their UTI share price forecasts range from $9.00 to $14.00. On average, they anticipate the company's share price to reach $10.60 in the next year. This suggests a possible upside of 46.0% from the stock's current price.
View analysts price targets for UTI or view top-rated stocks among Wall Street analysts.

Universal Technical Institute's stock was trading at $6.72 on January 1st, 2023. Since then, UTI shares have increased by 8.0% and is now trading at $7.26.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our UTI earnings forecast.

Universal Technical Institute will be holding an earnings conference call on Wednesday, February 8th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "5718590".

Universal Technical Institute, Inc. (NYSE:UTI) issued its quarterly earnings data on Monday, December, 12th. The company reported $0.18 earnings per share for the quarter. The business earned $110.64 million during the quarter, compared to the consensus estimate of $112.25 million. Universal Technical Institute had a net margin of 6.17% and a trailing twelve-month return on equity of 22.15%.

Universal Technical Institute updated its FY 2022 earnings guidance on Thursday, December, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $595.00 million-$610.00 million, compared to the consensus revenue estimate of $447.40 million.

7 employees have rated Universal Technical Institute Chief Executive Officer Jerome Grant on Glassdoor.com. Jerome Grant has an approval rating of 77% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Universal Technical Institute investors own include Dynavax Technologies (DVAX), General Electric (GE), Advanced Micro Devices (AMD), Ocular Therapeutix (OCUL), Sorrento Therapeutics (SRNE), Ampio Pharmaceuticals (AMPE), Pfizer (PFE), AbbVie (ABBV), Ardelyx (ARDX) and A10 Networks (ATEN).

Universal Technical Institute trades on the New York Stock Exchange (NYSE) under the ticker symbol "UTI."

Universal Technical Institute's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Greenwood Capital Associates LLC (0.35%), Strs Ohio (0.25%) and Rothschild Investment Corp IL (0.11%). Insiders that own company stock include Coliseum Capital Management, L, Jerome Alan Grant and Kimberly J Mcwaters.
View institutional ownership trends.

Shares of UTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of UTI stock can currently be purchased for approximately $7.26.

Universal Technical Institute (NYSE:UTI) has a market capitalization of $246.30 million and generates $418.77 million in revenue each year. The company earns $25.85 million in net income (profit) each year or $0.38 on an earnings per share basis.

The company employs 1,950 workers across the globe.

Universal Technical Institute's mailing address is 4225 EAST WINDROSE DRIVE SUITE 200, PHOENIX AZ, 85032. The official website for the company is www.uti.edu. The company can be reached via phone at (623) 445-9500, via email at investors@uti.edu, or via fax at 302-655-5049.